TSXV:CDX

Cloud DX Virtually Opens the Market

 Robert Kaul, Chief Executive Officer, Cloud DX Inc. ("Cloud DX" or the "Company") (TSXV: CDX) and his team joined Daniel Lubienietzky, Manager, Life Sciences, TMX Group to celebrate Cloud DX's new listing on TSX Venture Exchange and open the market.


Accelerating virtual healthcare's future, Cloud DX is making healthcare better for everyone. The Company's Connected Health remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place and deliver hospital-quality post-surgical care. Healthcare enterprises that partner with Cloud DX achieve better healthcare and patient outcomes, reduce the need for hospitalization/re-hospitalization and cut costs of healthcare delivery through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a Fast Company "World Changing Idea" finalist, a 2021 Edison Award finalist, and was recently named one of Canada's most prominent 10 telehealth providers. For more information visit: www.clouddx.com

For Market Openings: Media may pick up a feed from the TOC (television operations centre) for all market open ceremonies. The feed is named TSX Transmit 1 (SD-SDI) and is produced at the TMX Broadcast Centre and sent live to the TOC. To pick up the feed via the Dejero network, please contact avservices@tmx.com . The client feature video will begin playing on the TMX media wall at approximately 9:27 a.m. ET and the markets will open with the sound of a siren at 9:30 a.m. ET

Date: Monday April 19, 2021

Time: 9:00am - 9:30am

Place:  Virtually Broadcast

SOURCE TSX Venture Exchange

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/April2021/19/c4242.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Linius Technologies Limited

Linius Technologies Limited (ASX: LNU) – Trading Halt

Description

The securities of Linius Technologies Limited (‘LNU’) will be placed in trading halt at the request of LNU, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 8 July 2024 or when the announcement is released to the market.

Keep reading...Show less
XReality Group

Operator XR – Sales Update June 24

xReality Group Limited (“XRG” or the “Company”) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less
XReality Group

Operator XR –Awarded $800,000 Government Contract

xReality Group Limited (“XRG” or the “Company”) is pleased to announce the sale of multiple systems of its Operator XR Virtual Reality Training System to a new Australian State Government customer.
Keep reading...Show less
XReality Group (ASX:XRG)

XReality Group


Keep reading...Show less
Linius Technologies Limited

Linius Now Live with First Deployment in American Football

Linius Technologies Limited (ASX:LNU) (Linius or Company) – the only cloud-based solution that unlocks the value of video archives with immersive, deeply personalized viewer experiences via its Linius Media Solutions portfolio – is pleased to announce that the deployment of its sports solution, Whizzard, is now live with its customer Lone Star Conference.

Keep reading...Show less
Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy ("THT") also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug, IL-2. (See figure #1, below.) On the basis of efficacy data achieved in two different murine cancer models (triple negative breast cancer and malignant melanoma), the Company is now proceeding with safety and biocompatibility testing that will be required by regulating agencies to enter into human studies.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×